Dermatology
Non-Melanoma Skin Cancer — BCC and SCC
BCC vs SCC recognition, risk stratification, 2WW referral criteria, and treatment options
Source: NICE NG12 2015 / BAD NMSC Guidelines
Step 1 of ~10
info
Non-Melanoma Skin Cancer
BCC (basal cell carcinoma): most common skin cancer. Rarely metastasises. SCC (squamous cell carcinoma): can metastasise — especially high-risk sites (ear, lip, immunosuppressed). Key risk factors: UV exposure, fair skin, immunosuppression, previous skin cancer, radiation.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Dalteparin · Low Molecular Weight Heparin — VTE Treatment / Cancer-Associated Thrombosis
- Chlorhexidine gluconate with isopropyl alcohol · Skin antiseptic
- Chlorhexidine with cetrimide · Skin antiseptic / wound cleanser
- Barrier creams and ointments · Topical skin protectant
- Thiamine (IV/IM — Pabrinex) · Vitamin B1 (Thiamine) — deficiency treatment / Wernicke's encephalopathy prevention
- Dextrose 10% IV · IV glucose solution (hypoglycaemia treatment)
Pathways
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only. Always apply local guidelines and clinical judgement.